Clinical trials: Non Small Cell Lung Cancer Stage IIIB
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
This phase II trial studies the effect of bintrafusp alfa with pemetrexed and platinum-based chemotherapy (carboplatin or cisplatin) in treating patients with EGFR mutant non-small cell lung cancer that have spread to nearby…
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT04971187
- Testing
- Bintrafusp Alfa, Pemetrexed, Carboplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Non-squamous Non-small-cell Lung Cancer, Anlotinib
Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. The ALTER-0303 trial showed that patients with advanced non-small cell lung cancer (NSCLC) who received…
- Trial name
- NCT04012619
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Sichuan University
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
- Trial name
- NCT02179671
- Testing
- Gefitinib, AZD9291, Selumetinib+Docetaxel
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC
This is an open-label, single institution, phase II study of Sorafenib in combination with docetaxel and carboplatin in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00647426
- Testing
- Sorafenib + Docetaxel/Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer
Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00541099
- Testing
- bevacizumab, docetaxel
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphoma, Metastatic Malignant Solid Neoplasm
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer
- Trial name
- NCT03229278
- Testing
- Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Stage IV Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer
The purpose of this study is to find better treatment for lung cancer and to find out what effects the combined treatment of carboplatin and gemcitabine when given with or without dexamethasone have on cancer.
- Trial name
- NCT00247416
- Testing
- Gemcitabine, Dexamethasone, Carboplatin
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Susanne Arnold
Lung Cancer
Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544648
- Testing
- carboplatin, nab-paclitaxel, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
TG4010 and Nivolumab in Patients With Lung Cancer
This phase II trial studies how well TG4010 and nivolumab work in previously treated patients with non-small cell lung cancer. Vaccines that are made from a gene-modified virus, such as TG4010, may help the body build an…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
- Trial name
- NCT02823990
- Testing
- TG4010, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Megan Daly, MD
Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
This open-label, randomized, parallel arm study assessed the efficacy and safety of Tarceva (erlotinib) versus gemcitabine/cisplatin combination chemotherapy as first-line treatment in patients with stage IIIB/IV non-small cell…
- Trial name
- NCT01342965
- Testing
- Erlotinib, Chemotherapy
- Where
- 28 sites in China, Malaysia and 1 more
- Volunteers
- 217 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
- Trial name
- ATLANTIC (NCT02087423)
- Testing
- MEDI4736
- Where
- 139 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will assess the safety and tolerability, and make a preliminary assessment of activity, of a combination of pertuzumab and erlotinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT02507375
- Testing
- Erlotinib, Pertuzumab
- Where
- 3 sites in Belgium, Spain and 1 more
- Volunteers
- 17 people
- Sponsor
- Hoffmann-La Roche
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab work with or without erlotinib hydrochloride in treating non-smokers with advanced non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00976677
- Testing
- erlotinib hydrochloride, paclitaxel, carboplatin
- Where
- 108 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion
- Trial name
- NCT00126581
- Testing
- Carboplatin, Erlotinib, Erlotinib Hydrochloride
- Where
- 96 sites in United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.
- Trial name
- NCT00400803
- Testing
- Gemcitabine, Carboplatin, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lung Cancer
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different human tumor types including colon…
- Trial name
- NCT00064350
- Testing
- Sorafenib
- Where
- 141 sites in United States
- Volunteers
- 342 people
- Sponsor
- Eastern Cooperative Oncology Group
Carcinoma, Non-Small-Cell Lung
Phase II Iressa & Carbo/Gem in NSCLC
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.
- Trial name
- NCT00264498
- Testing
- Gefitinib, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
This phase II trial studies how well giving a hypofractionated boost to the primary tumor before standard chemotherapy and radiation therapy works in treating patients with stage II or III non-small cell lung cancer that cannot…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT02262325
- Testing
- hypofractionated radiation therapy, cisplatin, etoposide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
This randomized phase II trial studies pemetrexed disodium and sunitinib malate to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT00698815
- Testing
- Laboratory Biomarker Analysis, Pemetrexed Disodium, Sunitinib Malate
- Where
- 129 sites in United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)